Review study concludes THCV shows promise for type 2 diabetes and obesity

The non-psychoactive cannabinoid THCV has been reported to offer benefits for metabolic disorders such as diabetes and obesity through a variety of pathways. This study collected and analyzed existing research on the topic. It was published in the journal  AIMS Neuroscience in March 2025. 

Studies published in English were included if they met the following criteria:

focused on the role of THCV in metabolic processes related to obesity or type 2 diabetes

reported original findings from preclinical or clinical research.

While there are not many controlled human trials, they did say that the animal model studies were quite encouraging. The authors also noted the unique effects of THCV on the human endocannabinoid system - THC stimulates human CB1 receptors while THCV acts as an antagonist - the exact opposite effect.

Authors' conclusions:

THCV appears to modulate key metabolic pathways including appetite regulation, glucose homeostasis, and insulin sensitivity by antagonizing CB1 receptors and partially activating CB2 receptors

Early data from preclinical models and limited human trials suggest potential benefits for conditions such as obesity and type 2 diabetes

THCV represents a promising, yet still exploratory, adjunct candidate in the management of metabolic disorders

The full text paper is here at PubMed Central.

Source:

Mendoza S. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. AIMS Neurosci. 2025 Mar 12;12(1):32-43. doi: 10.3934/Neuroscience.2025003. PMID: 40270953; PMCID: PMC12011981.